Colarusso Chiara, Terlizzi Michela, Di Caprio Simone, Falanga Anna, D'Andria Emmanuel, d'Emmanuele di Villa Bianca Roberta, Sorrentino Rosalinda
Department of Pharmacy (DIFARMA), University of Salerno, 84084 Fisciano, SA, Italy.
Department of Pharmacy, University of Naples Federico II, 80131 Naples, NA, Italy.
Biomedicines. 2025 Jan 15;13(1):203. doi: 10.3390/biomedicines13010203.
The link between inflammation and cancer has been extensively studied over the years. While the inflammatory process can facilitate tumor establishment and progression, on the other hand, current clinical approaches aim to boost the immune system against the tumor mass. In this scenario, the conventional chemotherapy has proven to induce immunogenic cell death in that the release of danger-associated alarmins can foster the cytotoxic immunity following the blockade of immune checkpoints. The release of alarmins can activate the inflammasome pathway. Thus, one of the questions is as follows: can conventional anti-tumor drugs lead to inflammasome activation? And if so, is the resulting effect anti- or pro-tumor? In this review, we provide an overview on the role of the inflammasome in cancer.
多年来，炎症与癌症之间的联系已得到广泛研究。虽然炎症过程可促进肿瘤的形成和进展，但另一方面，目前的临床方法旨在增强免疫系统以对抗肿瘤块。在这种情况下，传统化疗已被证明可诱导免疫原性细胞死亡，因为危险相关警报素的释放可在免疫检查点阻断后促进细胞毒性免疫。警报素的释放可激活炎性小体途径。因此，问题之一如下：传统抗肿瘤药物能否导致炎性小体激活？如果可以，产生的效果是抗肿瘤还是促肿瘤？在本综述中，我们概述了炎性小体在癌症中的作用。
